Litcius/Paper detail

1496TiP Phase I study evaluating safety and tolerability of AMG 910, a half-life extended bispecific T cell engager targeting claudin-18.2 (CLDN18.2) in gastric and gastroesophageal junction (G/GEJ) adenocarcinoma

Florian Lordick, Joseph Chao, Elvira Buxó, Hanneke W.M. van Laarhoven, C.M.R. Lima, Sylvie Lorenzen, Farshid Dayyani, Volker Heinemann, Richard Greil, Sabine Stienen, Kohei Shitara

2020Annals of Oncology17 citationsDOI

Topics & Concepts

MedicineIrinotecanResponse Evaluation Criteria in Solid TumorsInternal medicineAdenocarcinomaOncologyPhases of clinical researchCancerCancer researchChemotherapyColorectal cancerBarrier Structure and Function StudiesRadiomics and Machine Learning in Medical ImagingCell Adhesion Molecules Research
1496TiP Phase I study evaluating safety and tolerability of AMG 910, a half-life extended bispecific T cell engager targeting claudin-18.2 (CLDN18.2) in gastric and gastroesophageal junction (G/GEJ) adenocarcinoma | Litcius